MELANOMA

This study tests a new treatment for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells, called T cells, which are genetically modified in a lab to better recognize and attack cancer cells. The main goa…

This early-stage study tests an experimental drug called AZD6244 combined with standard chemotherapies in 140 people with advanced solid tumors (breast, colon, lung, melanoma, kidney). The main goal is to find a safe dose and see how the body handles the drugs. Participants must …

This study compares two medications, infliximab and vedolizumab, for treating colitis (colon inflammation) caused by immune checkpoint inhibitor cancer therapy. About 47 adults with genitourinary cancer, melanoma, or non-small cell lung cancer who develop moderate to severe diarr…

This early-stage study tests a new cancer vaccine (p53MVA) combined with the immunotherapy drug pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The vaccine helps the immune system recognize and attack cancer cells, while pembrolizum…

This early-stage study tests whether a treatment made from a patient's own tumor-fighting immune cells (TIL) is safe for children, teenagers, and young adults with solid tumors that have come back or stopped responding to standard treatments. About 40 participants will receive th…

This early-phase study tests a new treatment for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein c…

This study is for people with advanced solid tumors (like lung, bladder, or skin cancer) that have stopped responding to standard immunotherapy drugs called PD-1/PD-L1 inhibitors. Researchers are testing a new combination of immune-boosting drugs to see if they can shrink tumors …

This study tests whether adding a new drug called relatlimab to the standard immunotherapy nivolumab helps people with advanced melanoma (skin cancer that has spread or cannot be removed by surgery) live longer without their cancer growing. About 714 participants who have not had…

This early-phase trial tests whether adding an experimental drug (MB097) to the standard immunotherapy pembrolizumab is safe and can help shrink tumors in people with advanced melanoma that did not respond to prior anti-PD1 treatment. About 41 adults with stage 3 or 4 melanoma wi…

This study tests whether GME751, a proposed copy of the cancer drug Keytruda, works similarly in people with stage II or III melanoma whose tumors were removed by surgery. About 322 adults will receive either GME751 or Keytruda to compare how the drug moves through the body, its …

This study tests giving two immunotherapy drugs (nivolumab and ipilimumab) before surgery to people with stage III melanoma. The goal is to shrink or kill the tumor and prevent the cancer from coming back. The study also uses an experimental PET scan to see if it can show how wel…

This study tests whether a combination of two immunotherapy drugs (zimberelimab and domvanalimab) can shrink tumors in people with advanced melanoma that has stopped responding to standard PD-1 inhibitors. The trial enrolled 8 adults with cutaneous melanoma or unknown primary mel…

This study tests a new drug called BI-1607 combined with two existing immunotherapies (ipilimumab and pembrolizumab) for people with advanced melanoma that has spread or cannot be removed. The goal is to see if adding BI-1607 helps the immune system better destroy cancer cells. A…

This early-phase study tests a new drug called AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment. The goal is to find the safest dose and see if it can shrink tumors in people with advanced cancers like melanoma, lung, and ovarian canc…

This study tested whether a combination of two immunotherapy drugs, nivolumab and low-dose ipilimumab, can help prevent melanoma from returning after surgical removal. The trial enrolled 22 adults with high-risk stage III or resected stage IV melanoma. Participants received the d…

This early-stage trial tests a new treatment for people with advanced solid tumors (like head and neck, melanoma, or lung cancer) that haven't responded to standard therapies. Doctors take a patient's own immune cells from the tumor, pick out the ones best at fighting cancer, gro…

This study tests whether adding AGuIX gadolinium-based nanoparticles to standard stereotactic radiation can better control brain metastases that are at high risk of coming back after radiation alone. About 134 adults with brain tumors from cancers like melanoma, lung, breast, or …

This study tests whether the immunotherapy drug nivolumab, given after complete surgical removal of stage IIB/C melanoma, can delay or prevent the cancer from coming back. About 790 adults and children who are at high risk for recurrence but have no current signs of disease will …

This study tests a drug called RP1, which is injected directly into skin cancer tumors. It is for people who have had an organ or stem cell transplant and now have advanced skin cancer. The goal is to see if RP1 can shrink tumors safely without harming the transplanted organ. Abo…

This study tests whether a combination of two experimental drugs (fianlimab and cemiplimab) works better than the current standard treatment (pembrolizumab) for people with advanced melanoma that cannot be removed by surgery. About 1,500 adults and teens with untreated advanced m…

This study looked at whether giving the immunotherapy drug pembrolizumab (Keytruda) after surgery for high-risk stage III melanoma helps keep the cancer from returning. About 1,000 participants were randomly assigned to receive either pembrolizumab or a placebo (inactive treatmen…

This study tests several combinations of the experimental drug LXH254 in people with advanced melanoma that has a BRAF or NRAS gene change and has stopped responding to earlier treatments. About 134 adults and teens (12 and older) will receive one of the drug combos to see if the…

This study tests an experimental drug called entrectinib in people with advanced solid tumors that have certain gene changes (NTRK, ROS1, or ALK). The drug aims to shrink or control the cancer by blocking signals that help it grow. About 534 adults with various cancers, including…

This study tests a new drug combination (BGB-A445 plus tislelizumab) in people with advanced bladder, kidney, or skin cancer that has spread. The goal is to see if the treatment can shrink tumors and how safe it is. About 113 participants will receive the drugs, which aim to boos…

This study tests whether adding two experimental vaccines (IO102/IO103) to a standard drug combination (nivolumab and relatlimab) is safe and works better for people with advanced melanoma that cannot be removed by surgery. About 43 adults who have not had prior treatment for the…

This study tests whether giving two targeted drugs (dabrafenib and trametinib) for 12 weeks before surgery can shrink melanoma that has spread to lymph nodes. It involves 35 adults with stage IIIB-C BRAF V600 mutation-positive melanoma. The main goal is to see how much cancer tis…

This early-phase study tests the safety and best dose of the drug veliparib when given with standard chemotherapy (carboplatin and paclitaxel) in adults with advanced solid tumors that also have liver or kidney dysfunction. The goal is to find out how the body processes the drugs…

This early-phase study tests a personalized cell therapy called T-Plex for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to recognize and attack cancer cells. The main goal is to check s…

This study tests whether adding a personalized mRNA cancer vaccine (mRNA-4157) to the immunotherapy drug pembrolizumab can better prevent melanoma from returning after surgery compared to pembrolizumab alone. About 267 people with high-risk melanoma that has spread to lymph nodes…

This study tests whether adding two oral targeted drugs (encorafenib and binimetinib) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with advanced melanoma that has a specific BRAF gene change. About 257 adults with untreated, advanced …

This study tests a new drug called ARRY-614 combined with standard immunotherapies (nivolumab or nivolumab+ipilimumab) in people with advanced solid tumors like lung, kidney, skin, and head/neck cancers. The first part finds a safe dose, and the second part checks if the combinat…

This early-phase study tests a new treatment called KSQ-001EX for people with advanced solid tumors like melanoma, lung, or head and neck cancers. The treatment uses a patient's own immune cells, which are modified in a lab to work better against cancer. The main goal is to see i…

This early-stage study tests a new drug called belvarafenib, alone or with other drugs (cobimetinib and nivolumab), in people with advanced melanoma that has a specific NRAS gene mutation and has stopped responding to standard immunotherapy. The main goals are to check safety and…

This study is for people with advanced melanoma that hasn't been treated yet. Researchers are testing whether adding other drugs to the standard treatment pembrolizumab can shrink tumors more effectively. The trial involves about 315 participants and focuses on safety and how wel…

This study tests an experimental drug called INBRX-106, given alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced solid tumors (like lung, head and neck, melanoma, stomach, kidney, or bladder cancer) that have stopped responding to standard treatment…

This early-phase study tests a personalized vaccine (NeoVax) combined with CDX-301 and standard immunotherapies (nivolumab or pembrolizumab) in 10 people with advanced melanoma. The goal is to find the safest dose and see if the vaccine boosts the immune system's attack on cancer…

This phase 2 trial tests whether adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe immune-related side effects in people with advanced melanoma that cannot be removed by surgery. About 71 participants will receive the three drugs during an …

This study looks at whether taking two drugs, dabrafenib and trametinib, after surgery can help prevent melanoma from returning in Chinese patients with a specific gene change (BRAF V600). The treatment is given to people with stage III melanoma that has been completely removed. …

This study tests a combination of two drugs (dapansutrile and pembrolizumab) in people with advanced melanoma that no longer responds to standard immunotherapy. The trial has two parts: first, finding the safest dose of dapansutrile when given with pembrolizumab, and second, chec…

This early-phase study tests a new drug (DKY709) alone or with another drug (PDR001) in adults with advanced solid tumors like lung cancer, melanoma, and breast cancer that have not responded to standard treatments. The main goal is to check safety and find the right dose. About …

This study tests whether adding dendritic cell immunization to T cell therapy and high-dose IL-2 helps T cells last longer in the body and fight metastatic melanoma better. About 1,230 participants with advanced melanoma will receive the treatment. The goal is to improve tumor sh…

This study tests an experimental drug called HFB200301, given alone or with another drug (tislelizumab), in adults with advanced solid tumors like stomach, kidney, or lung cancer. The goal is to find a safe dose and see how well people tolerate it. About 72 participants will take…

This study tests whether a new drug called ABP 206 works as well as the approved drug OPDIVO (nivolumab) for people with advanced melanoma that cannot be removed by surgery or has spread. About 633 adults who have not had prior treatment for their advanced melanoma will receive e…

This early-stage trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in 120 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find safe doses and check for side effects, while also measur…

This study tests an experimental drug called KIN-2787, taken as a pill, in about 400 adults with advanced solid tumors (like lung cancer or melanoma) that have certain gene changes (BRAF or NRAS). The main goals are to check safety, find the best dose, and see if the drug can shr…

This study tests two immunotherapy drugs, cobolimab and dostarlimab, together in children and young adults (up to age 21) with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The …

This early-phase study tests a new drug called AB248, alone or with another drug (pembrolizumab), in adults with advanced solid tumors (like lung, skin, head/neck, or kidney cancer) that have not been cured by other treatments. The main goal is to check the drug's safety and find…

This program gives adults with a specific type of advanced melanoma (BRAF mutation-positive) access to two targeted drugs, trametinib and dabrafenib, which work together to shrink tumors and control the disease. Participants must have melanoma that has spread or cannot be removed…

This early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma). The therapy takes a patient's own immune cells and genetically equips them to recognize and attack tumors that …

This study tests whether giving immunotherapy drugs (nivolumab alone or with ipilimumab) after melanoma surgery can prevent the cancer from coming back. The choice of treatment depends on how the tumor responds to a single dose of nivolumab before surgery. About 67 adults with st…

This study tests whether adding a personalized mRNA vaccine (V940) to the immunotherapy drug pembrolizumab can prevent melanoma from returning in people with high-risk stage II-IV melanoma. About 1,089 participants who had their melanoma surgically removed will receive either the…

This study tests a new experimental drug, HFB200603, either alone or combined with another cancer drug (tislelizumab), in adults with advanced solid tumors like kidney, lung, skin, stomach, or colorectal cancer. The goal is to find safe doses and understand side effects. About 83…

This study tests whether combining two immunotherapy drugs (fianlimab and cemiplimab) works better than one drug alone for people with high-risk, removable melanoma. About 151 participants will receive treatment before surgery, then continue after. The goal is to see if the combi…

This study tests an experimental drug called ensartinib in people with advanced melanoma that has a specific genetic change (ALK alteration). The goal is to see if the drug can shrink tumors or stop them from growing for at least 24 weeks. Participants must be 18 or older and hav…

This study tests whether the immunotherapy drugs nivolumab and ipilimumab, alone or together, can shrink melanoma tumors that have spread to the brain. It involves 76 adults with stage IV melanoma and at least one brain metastasis. The main goal is to see how many patients have t…

This study tests a combination of three drugs (nivolumab, ipilimumab, and cabozantinib) in people with advanced melanoma that cannot be removed by surgery. The goal is to see if this triple therapy can keep the cancer from growing for at least one year. Participants receive the d…

This early-phase study tests a new treatment called OBX-115, which uses a patient's own tumor-fighting immune cells that have been modified in the lab to include a protein (IL15) to help them survive longer. These cells are given along with acetazolamide to adults with metastatic…

This early-phase study tests a new drug, XL888, added to two existing melanoma drugs (vemurafenib and cobimetinib) for people with advanced BRAF-mutated melanoma that cannot be removed by surgery. The main goal is to find the safest dose of XL888 and see how well the combination …

This study tests an experimental antibody called GEN1042, alone or with the cancer drug pembrolizumab (with or without chemotherapy), in people with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The goal is to see if the treatment is safe …

This early-phase study tests a personalized cell therapy (ADP-A2M4CD8) for people with advanced cancers like lung, ovarian, or melanoma that have a specific marker called MAGE-A4. The treatment uses the patient's own immune cells, modified to better attack the cancer, and is give…

This study looks at whether a blood test can quickly and accurately find certain gene changes in people with advanced lung cancer or melanoma. These gene changes help doctors choose the right targeted therapy. The goal is to see if this blood-based method works as well as the sta…

This study looks at whether people with melanoma prefer getting their cancer medicine as a quick shot under the skin or as a longer IV drip. About 100 patients will try both ways and then say which they like better. The goal is to make treatment more convenient and comfortable fo…

This early-phase study tests a new type of proton therapy called ProGRID for people with large tumors (over 7 cm) that are hard to treat. The goal is to see if the treatment is safe and can be delivered successfully. About 11 adults with sarcoma or melanoma are taking part.

This study looks at adults with certain cancers (like lung, breast, kidney, or melanoma) that have spread to the brain. All participants are also receiving immunotherapy. The goal is to see if giving a lower dose of radiation over a few days causes fewer side effects than the sta…

This study looks at whether people with certain cancers prefer getting their pembrolizumab as a shot under the skin (subcutaneous) instead of through an IV. About 147 adults with lung cancer, kidney cancer, or melanoma will try both methods and report which they like better. The …

This study compares two ways of giving high-dose radiation to people whose cancer has spread to bones, spine, soft tissue, or lymph nodes. One group gets a single large dose in one day, the other gets a slightly higher total dose spread over three days. The goal is to see which s…

This study looks at whether a plant-based, high-fiber diet and regular exercise can change the gut microbiome in adults with melanoma who are receiving immunotherapy. Participants are split into two groups: one follows a strict diet and exercise plan, while the other receives sta…

This study follows 48 people with advanced melanoma who previously received the experimental drug combination fianlimab plus cemiplimab in an earlier trial. No new treatment is given; researchers track cancer status, overall health, and any late side effects over time. The goal i…

This study follows over 64,000 adults who grew up on farms to see if early-life exposures to pesticides and other agricultural factors are linked to cancer. Participants fill out an online questionnaire and may provide biological samples. Researchers will track cancer and other d…

This study compares a new total-body PET/CT scanner (uEXPLORER) to conventional PET/CT scanners in 180 adults with lung cancer, lymphoma, or melanoma. The goal is to find the shortest scan time on the new scanner that still produces images as clear as the standard scan. Participa…

This study looks at whether a simple blood test can help doctors track melanoma and spot when a treatment stops working. About 136 adults with stage IIB to IV melanoma will give blood samples over time. The goal is to see if changes in tumor DNA in the blood can predict the need …

This study collects leftover tissue, blood, and other body fluids from up to 6,000 people with benign or malignant tumors of the soft tissue, gastrointestinal tract, or abdomen. Researchers will use these samples in future lab studies to learn more about what causes these cancers…

This study tests a new imaging tool called MSOT that uses light and sound to create pictures of tumors. About 12 people with breast cancer or melanoma will get an MSOT scan before their usual biopsy. The goal is to see if MSOT can find tumors as well as standard methods like ultr…

This study looks at whether a health education campaign can help people in Oregon find melanoma (a serious skin cancer) earlier. Researchers will compare awareness and cancer data from Oregon (where the campaign runs) with data from Washington and Utah (where it does not). Up to …

This study looks back at medical records of 72 American Indian patients treated with immunotherapy for different cancers. Researchers want to see how long these patients lived without their cancer getting worse, their overall survival, and side effects compared to White patients.…

This study looks at how tumors evolve when patients with advanced head and neck cancer or melanoma receive immune checkpoint inhibitors. Researchers will analyze DNA from blood samples and tumor biopsies to see how the cancer changes under treatment. The goal is to better underst…

This study collects white blood cells and tumor samples from up to 7,000 cancer patients and healthy volunteers. The cells are used in the lab to grow large numbers of immune cells that may one day be given back to patients as experimental treatments. Participants do not receive …

This study looks at survival rates for people with cancers like melanoma, breast, colon, and lung cancer using data from Russian cancer registries. Researchers will analyze records from 100,000 patients to see how long they live after diagnosis. The goal is to better understand c…

This study tests a radioactive antibody called 124I-Hu3F8 to see how it moves through the body and attaches to tumors in people with melanoma, neuroblastoma, or sarcoma. Seven participants received the antibody followed by PET/CT scans at several time points. The goal is to under…

This early-phase study involves 14 adults with advanced head and neck, lung, or skin cancer who have not responded to prior treatments. Researchers use PET/CT scans to see how two experimental antibodies, BI 765063 and BI 770371, travel to tumors when given alongside another immu…

This study collects leftover tissue and blood samples from people with known or suspected cancer who are already scheduled for surgery or biopsy. Researchers will compare cancerous and normal tissues to find differences that could lead to new treatments. No extra procedures are d…

This study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. The goal is to track how cancer changes over time and during treatment. Researchers hope this will help them understand why some cancers resist therapy a…

This study tests whether analyzing the genes in a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced or hard-to-treat cancers (solid tumors, lymphoma, or myeloma) had their tumors genetically screened. Those with specific genetic c…

This study looks at whether a blood test that detects tiny bits of tumor DNA can help doctors decide when it's safe to stop immunotherapy in people with advanced melanoma or non-small cell lung cancer. About 39 patients who have been on immunotherapy for at least a year and show …

This study looks at whether a simple blood test that finds tiny bits of tumor DNA can spot melanoma coming back earlier than current methods like scans. About 467 people with high-risk melanoma will give blood samples over time. The goal is to see if this test is accurate and cou…

This study was designed to look at how community cancer clinics test for biomarkers in common cancers like lung, breast, and colorectal cancer. The goal was to find out if testing is fast and accurate, and to spot any differences in how tests are done. However, the study was with…

This study is testing a new gene test (Merlin Assay) to see if it can accurately predict whether melanoma has spread to nearby lymph nodes in newly diagnosed patients. About 1,820 adults with melanoma who are scheduled for a sentinel lymph node biopsy will provide tumor samples f…

This study looks back at medical records of children under 18 with advanced melanoma who were treated with the drug ipilimumab. Researchers want to see what serious side effects occurred over time. The goal is to better understand the long-term safety of this treatment in young p…

This study does not provide new treatment. Instead, it follows up to 1,150 people who previously received experimental cell or gene therapies for cancers like melanoma and neuroendocrine tumors. Participants will have yearly physical exams and blood tests for up to 15 years to mo…